There’s limited information about which parts of the SARS-CoV-2 virus elicit a strong immune response, which is extremely relevant in the design of promising vaccine candidates. Richard Scheuermann, Director of JCVI’s La Jolla facility, and his collaborators recently published a first analysis of the most promising epitope targets, based on analysis of SARS-CoV (2003) and the novel SARS-CoV-2 (2019). Richard will describe the findings, and also discuss:
– Some background on coronavirus features and its evolution
– Computational approaches in support of vaccine development
– B-cell versus T-cell strategies for fighting COVID-19
– How we can develop more effective vaccines using conserved epitope strategies
Recorded: March 31, 8:00am PST
Sign up to receive news about upcoming events, and the latest news in synthetic biology:
Join the conversation on:
Twitter:
Facebook:
LinkedIn:
Instagram:
